Time-to-Detection in Culture of Mycobacterium Tuberculosis NCT05568368

Updated 05/14/2024

Clinical Trial Details — Status: Completed

Administrative data
NCT number	NCT05568368
Other study ID #	22Infectio01
Secondary ID
Status	Completed
Phase
First received
Last updated
Start date	March 15, 2022
Est. completion date	September 15, 2022

Study information
Verified date	October 2022
Source	Centre Hospitalier Universitaire de Nice
Contact	n/a
Is FDA regulated	No
Health authority
Study type	Observational

Clinical Trial Summary

determination if time-to-detection in cultures of M. tuberculosis samples is more discriminating than acid-fast staining in transmission

Recruitment information / eligibility
Status	Completed
Enrollment	705
Est. completion date	September 15, 2022
Est. primary completion date	September 15, 2022
Accepts healthy volunteers	No
Gender	All
Age group	2 Years to 94 Years
Eligibility	Inclusion Criteria: - have at least 1 contact case explored for tuberculosis - latent tuberculosis infection Exclusion Criteria: -

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• No intervention
no intervention

Locations
Country	Name	City	State
France	Nice University Hospital	Nice

Sponsors *(1)*
Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France,

Outcome
Type	Measure	Description	Time frame	Safety issue
Primary	tuberculosis transmission	duration of Tuberculosis transmission between an infected person and a contact case	2 months
Primary	contact case tracking	screening time for contact cases	2 months

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04085133` - Prevalence and Burden of Bronchiectasis in Tuberculous Patients
	Recruiting	`NCT05017324` - Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial	N/A
	Completed	`NCT04207112` - Economic Evaluation of New MDR TB Regimens	Phase 2/Phase 3
	Completed	`NCT04044001` - BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)	Phase 1/Phase 2
	Withdrawn	`NCT03159975` - Safety and Immunogenicity Study of GX-70 in TB Patient	Phase 1
	Completed	`NCT02984579` - Line Probe Assay Evaluation Study	N/A
	Recruiting	`NCT04930978` - Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
	Not yet recruiting	`NCT05477966` - A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress
	Completed	`NCT05097638` - Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.
	Active, not recruiting	`NCT05045391` - Pulmonary Aspergillosis in Tuberculosis Patients
	Completed	`NCT02754765` - Evaluating Newly Approved Drugs for Multidrug-resistant TB	Phase 3
	Active, not recruiting	`NCT03896685` - Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)	Phase 3